News and Announcements
Proteomics to Expand Operations in Indian Market
- Published April 15, 2016 10:40AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th April 2016, ASX Announcement
Highlights:
- PILL to expand to Indian biotech sector – rapidly growing global biotech hub forecast to be worth $US100b by 2025.
- PILL to conduct India trade visit this month to drive uptake to biosimilars analytics and biomarker services.
- Company appoints Regional Sales Manager for India as part of its Indian growth strategy.
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce the expansion of its operations in the massive Indian biotechnology industry.
India represents a significant, global biotechnology jurisdiction, forecast to grow at an average rate of 30% per year to be worth US$100 billion by 2015. PILL has operated successfully in India since 2004, and will now expand its operations to take advantage burgeoning opportunities for its proteomics-based services.
To view the full article please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
